Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Biohaven Ltd.

BHVN

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Last trade $13.39
Day change -$0.415 (-3.01%)
Day range $13.21 – $14.02
Volume 797,143
Market cap $2.08B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.08B
Price / earnings
—
Price / book
-21.22×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.37×

Profitability

Earnings per share
-$3.59
Return on assets
-205.81%
Return on equity
552.36%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-2.69×
Current ratio
3.05×
Quick ratio
3.05×
Cash ratio
1.53×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$473.17M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BHVN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$24.57M$24.09M$26.6M$20.79M$28.21M$27.33M$33.98M$22.46M
Research and development$101.85M$100.81M$103.83M$121.95M$141.17M$184.37M$187.58M$167.47M
Total operating expenses$126.42M$124.9M$130.43M$142.73M$169.38M$211.7M$221.56M$189.93M
Operating income-$126.42M-$124.9M-$130.43M-$142.73M-$169.38M-$211.7M-$221.56M-$189.93M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$129.34M-$136.92M-$130.26M-$145.2M-$173.22M-$197.89M-$221.07M-$186.8M
Income taxes-$64K$391K$272K$351K$221K$261K$609K$48K
Net income-$129.28M-$137.31M-$130.53M-$145.56M-$173.44M-$198.15M-$221.68M-$186.84M
Net income attributable to common shareholders-$129.28M-$137.31M-$130.53M-$145.56M-$173.44M-$198.15M-$221.68M-$186.84M
EBITDA-$124.2M-$122.64M-$128.06M-$140.16M-$166.26M-$209.72M-$219.32M-$187.47M
Basic earnings per share-$0.86-$0.91-$0.88-$1.21-$1.64-$1.94-$2.17-$1.85
Diluted earnings per share-$0.86-$0.91-$0.88-$1.21-$1.64-$1.94-$2.17-$1.85

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development

Bexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design.

The Motley Fool

Why Biohaven Stock Was Rocking the Market This Week

Biohaven announced a licensing and collaboration deal with SK Biopharmaceuticals worth up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim for focal epilepsy treatment. Additionally, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. These developments drove Biohaven stock up more than 16% week-to-date.

The Motley Fool

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused on late-stage programs including a degrader platform and Phase 2 obesity candidate with data expected in H2 2026, while maintaining a strengthened balance sheet with $500.9 million in cash.

Benzinga

Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know

Biohaven shares surged 6.65% in regular trading and 3.42% in after-hours trading following an investor presentation at the J.P. Morgan Healthcare Conference. The company presented Phase 1 data for BHV-1400 showing significant reductions in IgA nephropathy markers and clinical improvements in patients. Multiple catalysts are expected in 2026, including Phase 2 obesity trial results, pivotal epilepsy trial results, and initiation of trials for other candidates. However, the stock has declined 67.11% over the past 12 months and is trading near its 52-week lows.

Benzinga

Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED)

U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. Economist Justin Wolfers cautioned that U.S. market gains are lagging global markets significantly.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.